In Depth 6 Nov 2023 The biggest private biotech investments in October 2023 The companies Aiolos Bio, MapLight Therapeutics and Agomab Therapeutics bagged the biggest biotech investments in October 2023. Around the world, biomaterials, central nervous system and musculoskeletal disorder players attracted the most investor interest. October 2023 saw a lot of fundraising taking place both in and out of healthcare in the U.S. and Europe. However, the […] November 6, 2023 - 3 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 9 Oct 2023 The biggest private biotech investments in September 2023 The companies Generate Biomedicines, Apollo Therapeutics and Nimbus Therapeutics bagged the biggest biotech investments in September 2023. Around the world, drug discovery and oncology players attracted the biggest funding rounds. As we made our way into autumn in the Northern Hemisphere, September 2023 saw some big funding rounds take place around the globe, particularly within […] October 9, 2023 - 3 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 4 Sep 2023 The biggest private biotech investments in August 2023 The companies Genesis Therapeutics, ADARx Pharmaceuticals, and Abcuro bagged the biggest biotech investments in August 2023. Around the world, companies focused on immunology, genetic disorders, and metabolic disorders attracted the biggest funding rounds. Overall, quite a lot of biotech fundraising took place in August 2023. As always, there were some big rounds within the U.S. […] September 4, 2023 - 3 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 27 Jul 2023 Recbio shingles vaccine clinical trial approved Jiangsu Recbio Technology Co., Ltd. has received notice of acceptance from China’s National Medical Products Administration (NMPA) to start a clinical trial for its self-developed novel adjuvanted recombinant shingles vaccine, REC610. Within 60 days from the date of acceptance, the company may carry out clinical trials in accordance with the submitted plan if no negative […] July 27, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 20 Jul 2023 Endometrial cancer drug receives breakthrough therapy designation in China HUTCHMED (China) Limited has announced that the Center for Drug Evaluation of China’s National Medical Products Administration (NMPA) has granted Breakthrough Therapy Designation (BTD) to the combination of fruquintinib and sintilimab (a PD-1 antibody) for the treatment of patients with advanced endometrial cancer with pMMR tumors that have failed at least one line of platinum-based […] July 20, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 19 Jul 2023 Genetic engineering giants: is China poised to lead the way? For many people, when they hear China and genetic engineering in the same sentence, it is often synonymous with scandal, and gene-edited babies may spring to mind. And, although it is true that nearly five years ago, researcher He Jiankui infamously claimed he had created the first ever gene-edited babies, before going to prison for […] July 19, 2023 - 7 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 5 Jul 2023 Narcolepsy drug gets Chinese approval RareStone Group, a rare disease-focused company aiming to establish the first rare disease ecosystem in China, has announced that the Chinese National Medical Products Administration (NMPA) has approved pitolisant (Wakix) for the treatment of excessive daytime sleepiness (EDS) or cataplexy in adult patients with narcolepsy. In China, pitolisant is the first approved innovative drug for […] July 5, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 4 Jul 2023 Innovent and IASO Bio obtain approval for CAR-T multiple myeloma treatment Innovent Biologics, Inc. and IASO Biotechnology have announced that China’s National Medical Products Administration (NMPA) has approved the New Drug Application (NDA) for FUCASO (Equecabtagene Autoleucel). FUCASO is the first fully-human BCMA-directed chimeric antigen receptor (CAR) T-cell therapy for adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least three prior […] July 4, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 23 Jun 2023 Breakthrough treatment for skin infections? A research team led by Kelvin Yeung from the Department of Orthopaedics and Traumatology, School of Clinical Medicine, LKS Faculty of Medicine, the University of Hong Kong (HKUMed) has designed a new microneedle patch that provides an effective non-antibiotic approach for the treatment of skin infections. The design engineered with ultrasound-responsive zinc-based metal-organic framework (MOF) […] June 23, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 20 Jun 2023 Clearance for anti-tumor bispecific antibody trial TG ImmunoPharma Co., Ltd. (TGI), which focuses on the development of novel immuno-oncology therapies, says the FDA has granted clearance for the clinical trial of TGI-6, its bispecific antibody. TGI-6 targets unique tumor-associated antigens (TAA) and CD3 molecules simultaneously, enabling potent anti-tumor responses. TGI said the antibody demonstrates exceptional anti-tumor activity, favorable safety profiles, and […] June 20, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 23 May 2023 HuidaGene Therapeutics creates world’s first ‘G to Y’ DNA base-editor HuidaGene Therapeutics, a clinical-stage genome-editing company, says the National Science Review has published data from its study of the world’s first DNA base editor converting guanine to cytosine/thymine (pyrimidine), or G-to-Y. The company has filed an international patent application for the glycosylase-based guanine base editor (gGBE) and owns the exclusive global rights to the underlying […] May 23, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 16 May 2023 Researchers’ mutation discovery offers new Alzheimer’s hope Alzheimer’s disease (AD) is a progressive neurodegenerative disorder affecting tens of millions of people worldwide, and it is the most common cause of dementia. Early-onset AD is typically associated with mutations in the genes APP, PSEN1, and PSEN2, leading to a more aggressive form of the disease with atypical symptoms. In contrast, the newly discovered […] May 16, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email